Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02954796 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02954796 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 27 participants.
The verdict
NCT02954796, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study tests the safety of a drug called SGN-CD352A, to find out what its side effects are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple myeloma.
Interventions
- DRUG SGN-CD352A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-12 |
| Est. Completion | 2019-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02954796
The ClinicalTrials.gov registry entry for NCT02954796 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-CD352A is the first listed.
NCT02954796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02954796 about?
NCT02954796 is a clinical study titled "A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma". This study tests the safety of a drug called SGN-CD352A, to find out what its side effects are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple myeloma.
What is the current status of trial NCT02954796?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2016-12. Estimated completion is 2019-07-17.
What interventions are being tested in trial NCT02954796?
The interventions under investigation include: SGN-CD352A (DRUG).
Who is sponsoring clinical trial NCT02954796?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.